
Biologic achieves improvements in bullous pemphigoid
A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) has met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease. In the study, five times more Dupixent patients achieved sustained disease remission compared to those on placebo. Read More















